JESSICA EVANS: Open Payments
NPI 1710609706 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,844 in 117 payments from 19 companies in 2025. Trend: 2023 $167 · 2024 $1,097 · 2025 $3,844
Food & beverage: $3,844
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 24 | $639 |
| Bayer Healthcare Pharmaceuticals Inc. | 15 | $509 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $497 |
| Novo Nordisk Inc | 10 | $267 |
| PFIZER INC. | 13 | $248 |
| E.R. Squibb & Sons, L.L.C. | 2 | $245 |
| Lilly USA, LLC | 2 | $233 |
| Alnylam Pharmaceuticals Inc. | 3 | $189 |
| Medtronic, Inc. | 5 | $182 |
| SCPHARMACEUTICALS INC. | 3 | $159 |
Products named: REPATHA, JARDIANCE, Kerendia, CAMZYOS, AMVUTTRA, VYNDAQEL, FUROSCIX, Attruby.
Industry payments across CA — which companies pay providers there.
